Ciborowski P, Flock J I, Wadström T
Department of Medical Microbiology, University of Lund, Sweden.
J Med Microbiol. 1992 Dec;37(6):376-81. doi: 10.1099/00222615-37-6-376.
A protein (gal-FnBP), constructed by fusion of the genes encoding beta-galactosidase of Escherichia coli and the binding domains of fibronectin-binding protein (FnBP) of Staphylococcus aureus was used. FnBP is a surface protein responsible for attachment of bacteria to extracellular matrix of various host tissues. Gal-FnBP is more stable and can be produced in larger quantities than native FnBP. The binding specificity of this fusion protein was established in a Western blot analysis. Treatment of gal-FnBP with formalin inactivated the binding capacity of the protein but immunogenicity was retained. Immunisation of mice with formalin-treated gal-FnBP resulted in high antibody titres against the fibronectin-binding part of this fusion protein. These antibodies were measured by their ability to block the specific binding of fibronectin to gal-FnBP in a blocking assay. Sera raised against formalin-treated gal-FnBP and non-treated gal-FnBP blocked this binding to 40 and 25% respectively, thereby indicating the usefulness of gal-FnBP as a vaccine component.
使用了一种蛋白质(gal-FnBP),它是通过将编码大肠杆菌β-半乳糖苷酶的基因与金黄色葡萄球菌纤连蛋白结合蛋白(FnBP)的结合域融合构建而成的。FnBP是一种表面蛋白,负责细菌与各种宿主组织细胞外基质的附着。Gal-FnBP比天然FnBP更稳定,且能大量生产。通过蛋白质印迹分析确定了这种融合蛋白的结合特异性。用福尔马林处理gal-FnBP会使该蛋白的结合能力失活,但免疫原性得以保留。用福尔马林处理过的gal-FnBP免疫小鼠可产生针对该融合蛋白纤连蛋白结合部分的高抗体滴度。在阻断试验中,通过它们阻断纤连蛋白与gal-FnBP特异性结合的能力来检测这些抗体。用福尔马林处理过的gal-FnBP和未处理的gal-FnBP免疫产生的血清分别能阻断40%和25%的这种结合,从而表明gal-FnBP作为疫苗成分的有效性。